Research Analysts Offer Predictions for Insulet Q4 Earnings

Insulet Co. (NASDAQ:PODD) – Equities researchers at Leerink Partnrs dropped their Q4 2024 earnings per share (EPS) estimates for shares of Insulet in a research report issued to clients and investors on Monday, November 25th. Leerink Partnrs analyst M. Kratky now forecasts that the medical instruments supplier will post earnings per share of $0.97 for the quarter, down from their prior forecast of $0.99. The consensus estimate for Insulet’s current full-year earnings is $3.22 per share. Leerink Partnrs also issued estimates for Insulet’s Q2 2025 earnings at $0.87 EPS, Q3 2025 earnings at $1.14 EPS, Q4 2025 earnings at $1.20 EPS, FY2025 earnings at $3.89 EPS, FY2026 earnings at $5.21 EPS and FY2027 earnings at $6.49 EPS.

PODD has been the subject of several other reports. Raymond James boosted their target price on shares of Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a research report on Monday, October 14th. Canaccord Genuity Group increased their target price on shares of Insulet from $236.00 to $269.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th. Morgan Stanley raised their target price on Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a report on Monday, November 11th. Piper Sandler upped their price target on Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 17th. Finally, BTIG Research boosted their target price on Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Three analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat, Insulet currently has a consensus rating of “Moderate Buy” and an average price target of $253.27.

Insulet Trading Up 1.4 %

NASDAQ:PODD opened at $266.58 on Tuesday. The company has a market capitalization of $18.70 billion, a P/E ratio of 45.65, a P/E/G ratio of 4.02 and a beta of 1.22. The stock’s 50 day moving average price is $241.97 and its 200 day moving average price is $211.65. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. Insulet has a 52 week low of $160.19 and a 52 week high of $279.40.

Institutional Trading of Insulet

Several large investors have recently added to or reduced their stakes in the company. Baillie Gifford & Co. boosted its holdings in shares of Insulet by 20.7% in the 3rd quarter. Baillie Gifford & Co. now owns 2,275,701 shares of the medical instruments supplier’s stock worth $529,669,000 after acquiring an additional 389,639 shares in the last quarter. Geode Capital Management LLC boosted its stake in Insulet by 1.3% in the third quarter. Geode Capital Management LLC now owns 1,738,601 shares of the medical instruments supplier’s stock worth $403,339,000 after purchasing an additional 22,850 shares in the last quarter. Clearbridge Investments LLC grew its holdings in shares of Insulet by 6.0% during the second quarter. Clearbridge Investments LLC now owns 1,339,763 shares of the medical instruments supplier’s stock worth $270,364,000 after purchasing an additional 75,526 shares during the last quarter. American Century Companies Inc. increased its stake in shares of Insulet by 18.7% in the second quarter. American Century Companies Inc. now owns 885,669 shares of the medical instruments supplier’s stock valued at $178,728,000 after buying an additional 139,246 shares in the last quarter. Finally, Westfield Capital Management Co. LP raised its holdings in shares of Insulet by 27.6% in the third quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier’s stock valued at $175,697,000 after buying an additional 163,388 shares during the last quarter.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.